New lipid lowering drugs and new effects of old drugs

Current Opinion in Lipidology

Volumn 8, Issue 6, 1997, Pages 362-368

  Dujovne, Carlos A ^a  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BAYCHOL; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CLOFIBRATE; CYTOCHROME P450; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; NICERITROL; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; RESIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DYSPEPSIA; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SHORT SURVEY; SLOW RELEASE FORMULATION;

EID: 0030829218     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199712000-00007     Document Type: Short Survey

References (31)

1. Treasure C, Klein J, Weintraub W, Talley J, Stillabower M, Kosinski A, Zhang J, Boccuzzi S, Cedarholm J, Alexander H: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEJM 1995, 332:481-487.
2. Anderson T, Meredith I, Yeung A, Frei B, Selwyn A, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. NEJM 1995, 332:488-493.
3. O'Driscoll G, Green D, Taylor R: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131. Importance of demonstration of the same endothelial function improvement following just 1 month of simvastatin therapy.
4. Eashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelial-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
5. National Cholesterol Education Program: Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994, 89:1329-1445.
6. Dujovne C, Chremos A, Pool J, Schnaper H, Bradford R, Shear C, Higgins J, Downton M, Franklin F, Nash D, Gould A, Langendorfer A: Expanded clinical evaluation of lovastatin (EXCEL) study results: IV additional perspectives on the tolerability of lovastatin. Am J Med 1991, 191 (suppl 1B):25S-30S.
7. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
8. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedwald W: Fifteen year mortality in Coronary Drug Project Patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
9. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ: Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Ann NY Acad Sci 1995, 748:407-417.
10. Illingworth D, Stein E, Mitchell Y, Dujovne C, Frost P, Knopp R, Tun P, Zupkis R, Greguski R: Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Int Med 1994, 154:1586-1595.
11. McKenney J, Proctor J, Harris S, Chincili V: A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271:672-677.
12. Morgan J, Capuzzi D, Guyton J, Centor R, Goldberg R, Robbins D, DiPette D, Jenkins S, Marcovina S: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1996, 1:195-202. A new study on control release niacin questioning the real or higher capacity on control release niacin for hepatotoxic effects and suggesting that the type of control release preparation may have an impact on the hepatotoxicity chances.
13. Gray D, Morgan T, Chretien S, Kashyap M: Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994, 121:252-258.
14. Pravastatin Multicenter Study Group II: Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Int Med 1993, 153:1321-1329.
15. Schrott H, Stein E, Dujovne C, Davidson M, Goris G, Oliphant T, Phillips J, Shawaryn G: Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Card 1995, 75:34-39.
16. Ericsson G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853. This is the first angiographic documentation of the fibrate effecting the regression and progression of coronary heart disease.
17. de Faire U, Ericsson C, Grip L, Nilssons J, Svane B, Hamstens A: Secondary preventive potential of lipid-lowering drugs. The bezafibrate coronary atherosclerosis intervention trial (BECAIT). Eur Heart J 1996, 17(suppl F):37-42.
18. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI and the REGRESS Study Group: Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study. Circulation 1995, 91:2528-2540.
19. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638.
20. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, Manttari M, Frick MH: The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994, 235:31-39.
21. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer A, Macfarlane P, McKillop J: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
22. Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T, Brown L, Warnica J, Arnold J, Wun C, Davis B, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction In patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009. This is the first trial showing that average cholesterol levels need to be lowered in people who have coronary heart disease. Lowering of those levels results in improving cardiovascular morbidity and all causes of mortality.
23. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994, 344:1383-1389.
24. Regnström J, Walldius G, Nilsson S, Elinder L, Johansson J, Mölgaard J, Holme I, Olsson A, Nilsson J: The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996, 125:217-229.
25. Tardif J, Côté G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, De Guise P: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. NEJM 1997, 337:365-372. This is the first positive trial of antioxidants preventing restenosis postangioplasty.
26. Dujovne C, Harris W, Gerrond L, Fan J, Muzio F: Comparison of effects of probucol vs. vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am J Cardiol 1994, 74:38-42.
27. Stein J, Rosenson R: Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997, 157:1170-1176.
28. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E: Effect of oral estradiol of Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med 1996, 156:866-872.
29. Illingworth D, Stein E, Mitchell Y, Dujovne C, Frost P, Knopp R, Tun P, Zupkis R, Greguski R: Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994, 154:1586-1595.
30. Suefuji H, Ogawa H, Yasue H, Imoto N, Sakamoto T, Miyao Y, Kaikita K, Soejima H, Nishiyama K: Effect of niceritrol on fibrinolysis and lipoprotein(a) levels in patients with coronary artery disease. Coronary Artery Disease 1996, 7:167-172.
31. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, and the ROXIS Study Group: Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997, 350:404-407.